Home Healthcare IT Infectious Disease Point-of-Care Diagnostics Market

Infectious Disease Point-of-Care Diagnostics Market Size, Share & Trends Analysis Report By Technology (Lateral Flow Immunoassay, Agglutination Test, Flow-through test/Immunoconcentration Assay, Molecular Diagnostics, Others), By Disease (Respiratory Infections, COVID-19, Influenza A/B, RSV, Others, Sexually Transmitted Infections), HIV (), Chlamydia (), Gonorrhea (), Syphilis (), Others (Vector-Borne Diseases, Hepatitis & Liver Diseases, Tuberculosis, Hospital-Acquired Infections, Others), By End Use (Hospitals & Clinics, Diagnostic Laboratories, Home Healthcare, Assisted Living Healthcare Facilities, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 29, 2026 | Author: Dhanashri B | Format: | Report Code: SRHI58340DR | Pages: 210
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Regulatory Framework
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  7. ESG Trends
  8. Global Infectious Disease Point-of-Care Diagnostics Market Size Analysis
    1. Global Infectious Disease Point-of-Care Diagnostics Market Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
  9. North America Market Analysis
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
    10. U.S.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Lateral Flow Immunoassay
          1. By Value
        3. Agglutination Test
          1. By Value
        4. Flow-through test/Immunoconcentration Assay
          1. By Value
        5. Molecular Diagnostics
          1. By Value
        6. Others
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Respiratory Infections
          1. By Value
        3. COVID-19
          1. By Value
        4. Influenza A/B
          1. By Value
        5. RSV
          1. By Value
        6. Others
          1. By Value
        7. Sexually Transmitted Infections
          1. By Value
      3. HIV
        1. Introduction
          1. HIV By Value
      4. Chlamydia
        1. Introduction
          1. Chlamydia By Value
      5. Gonorrhea
        1. Introduction
          1. Gonorrhea By Value
      6. Syphilis
        1. Introduction
          1. Syphilis By Value
      7. Others
        1. Introduction
          1. Others By Value
        2. Vector-Borne Diseases
          1. By Value
        3. Hepatitis & Liver Diseases
          1. By Value
        4. Tuberculosis
          1. By Value
        5. Hospital-Acquired Infections
          1. By Value
        6. Others
          1. By Value
      8. By End Use
        1. Introduction
          1. End Use By Value
        2. Hospitals & Clinics
          1. By Value
        3. Diagnostic Laboratories
          1. By Value
        4. Home Healthcare
          1. By Value
        5. Assisted Living Healthcare Facilities
          1. By Value
        6. Others
          1. By Value
    11. Canada
  10. Europe Market Analysis
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
    10. U.K.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Lateral Flow Immunoassay
          1. By Value
        3. Agglutination Test
          1. By Value
        4. Flow-through test/Immunoconcentration Assay
          1. By Value
        5. Molecular Diagnostics
          1. By Value
        6. Others
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Respiratory Infections
          1. By Value
        3. COVID-19
          1. By Value
        4. Influenza A/B
          1. By Value
        5. RSV
          1. By Value
        6. Others
          1. By Value
        7. Sexually Transmitted Infections
          1. By Value
      3. HIV
        1. Introduction
          1. HIV By Value
      4. Chlamydia
        1. Introduction
          1. Chlamydia By Value
      5. Gonorrhea
        1. Introduction
          1. Gonorrhea By Value
      6. Syphilis
        1. Introduction
          1. Syphilis By Value
      7. Others
        1. Introduction
          1. Others By Value
        2. Vector-Borne Diseases
          1. By Value
        3. Hepatitis & Liver Diseases
          1. By Value
        4. Tuberculosis
          1. By Value
        5. Hospital-Acquired Infections
          1. By Value
        6. Others
          1. By Value
      8. By End Use
        1. Introduction
          1. End Use By Value
        2. Hospitals & Clinics
          1. By Value
        3. Diagnostic Laboratories
          1. By Value
        4. Home Healthcare
          1. By Value
        5. Assisted Living Healthcare Facilities
          1. By Value
        6. Others
          1. By Value
    11. Germany
    12. France
    13. Spain
    14. Italy
    15. Russia
    16. Nordic
    17. Benelux
    18. Rest of Europe
  11. APAC Market Analysis
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
    10. China
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Lateral Flow Immunoassay
          1. By Value
        3. Agglutination Test
          1. By Value
        4. Flow-through test/Immunoconcentration Assay
          1. By Value
        5. Molecular Diagnostics
          1. By Value
        6. Others
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Respiratory Infections
          1. By Value
        3. COVID-19
          1. By Value
        4. Influenza A/B
          1. By Value
        5. RSV
          1. By Value
        6. Others
          1. By Value
        7. Sexually Transmitted Infections
          1. By Value
      3. HIV
        1. Introduction
          1. HIV By Value
      4. Chlamydia
        1. Introduction
          1. Chlamydia By Value
      5. Gonorrhea
        1. Introduction
          1. Gonorrhea By Value
      6. Syphilis
        1. Introduction
          1. Syphilis By Value
      7. Others
        1. Introduction
          1. Others By Value
        2. Vector-Borne Diseases
          1. By Value
        3. Hepatitis & Liver Diseases
          1. By Value
        4. Tuberculosis
          1. By Value
        5. Hospital-Acquired Infections
          1. By Value
        6. Others
          1. By Value
      8. By End Use
        1. Introduction
          1. End Use By Value
        2. Hospitals & Clinics
          1. By Value
        3. Diagnostic Laboratories
          1. By Value
        4. Home Healthcare
          1. By Value
        5. Assisted Living Healthcare Facilities
          1. By Value
        6. Others
          1. By Value
    11. Korea
    12. Japan
    13. India
    14. Australia
    15. Taiwan
    16. South East Asia
    17. Rest of Asia-Pacific
  12. Middle East and Africa Market Analysis
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
    10. UAE
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Lateral Flow Immunoassay
          1. By Value
        3. Agglutination Test
          1. By Value
        4. Flow-through test/Immunoconcentration Assay
          1. By Value
        5. Molecular Diagnostics
          1. By Value
        6. Others
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Respiratory Infections
          1. By Value
        3. COVID-19
          1. By Value
        4. Influenza A/B
          1. By Value
        5. RSV
          1. By Value
        6. Others
          1. By Value
        7. Sexually Transmitted Infections
          1. By Value
      3. HIV
        1. Introduction
          1. HIV By Value
      4. Chlamydia
        1. Introduction
          1. Chlamydia By Value
      5. Gonorrhea
        1. Introduction
          1. Gonorrhea By Value
      6. Syphilis
        1. Introduction
          1. Syphilis By Value
      7. Others
        1. Introduction
          1. Others By Value
        2. Vector-Borne Diseases
          1. By Value
        3. Hepatitis & Liver Diseases
          1. By Value
        4. Tuberculosis
          1. By Value
        5. Hospital-Acquired Infections
          1. By Value
        6. Others
          1. By Value
      8. By End Use
        1. Introduction
          1. End Use By Value
        2. Hospitals & Clinics
          1. By Value
        3. Diagnostic Laboratories
          1. By Value
        4. Home Healthcare
          1. By Value
        5. Assisted Living Healthcare Facilities
          1. By Value
        6. Others
          1. By Value
    11. Turkey
    12. Saudi Arabia
    13. South Africa
    14. Egypt
    15. Nigeria
    16. Rest of MEA
  13. LATAM Market Analysis
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Lateral Flow Immunoassay
        1. By Value
      3. Agglutination Test
        1. By Value
      4. Flow-through test/Immunoconcentration Assay
        1. By Value
      5. Molecular Diagnostics
        1. By Value
      6. Others
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Respiratory Infections
        1. By Value
      3. COVID-19
        1. By Value
      4. Influenza A/B
        1. By Value
      5. RSV
        1. By Value
      6. Others
        1. By Value
      7. Sexually Transmitted Infections
        1. By Value
    4. HIV
      1. Introduction
        1. HIV By Value
    5. Chlamydia
      1. Introduction
        1. Chlamydia By Value
    6. Gonorrhea
      1. Introduction
        1. Gonorrhea By Value
    7. Syphilis
      1. Introduction
        1. Syphilis By Value
    8. Others
      1. Introduction
        1. Others By Value
      2. Vector-Borne Diseases
        1. By Value
      3. Hepatitis & Liver Diseases
        1. By Value
      4. Tuberculosis
        1. By Value
      5. Hospital-Acquired Infections
        1. By Value
      6. Others
        1. By Value
    9. By End Use
      1. Introduction
        1. End Use By Value
      2. Hospitals & Clinics
        1. By Value
      3. Diagnostic Laboratories
        1. By Value
      4. Home Healthcare
        1. By Value
      5. Assisted Living Healthcare Facilities
        1. By Value
      6. Others
        1. By Value
    10. Brazil
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Lateral Flow Immunoassay
          1. By Value
        3. Agglutination Test
          1. By Value
        4. Flow-through test/Immunoconcentration Assay
          1. By Value
        5. Molecular Diagnostics
          1. By Value
        6. Others
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Respiratory Infections
          1. By Value
        3. COVID-19
          1. By Value
        4. Influenza A/B
          1. By Value
        5. RSV
          1. By Value
        6. Others
          1. By Value
        7. Sexually Transmitted Infections
          1. By Value
      3. HIV
        1. Introduction
          1. HIV By Value
      4. Chlamydia
        1. Introduction
          1. Chlamydia By Value
      5. Gonorrhea
        1. Introduction
          1. Gonorrhea By Value
      6. Syphilis
        1. Introduction
          1. Syphilis By Value
      7. Others
        1. Introduction
          1. Others By Value
        2. Vector-Borne Diseases
          1. By Value
        3. Hepatitis & Liver Diseases
          1. By Value
        4. Tuberculosis
          1. By Value
        5. Hospital-Acquired Infections
          1. By Value
        6. Others
          1. By Value
      8. By End Use
        1. Introduction
          1. End Use By Value
        2. Hospitals & Clinics
          1. By Value
        3. Diagnostic Laboratories
          1. By Value
        4. Home Healthcare
          1. By Value
        5. Assisted Living Healthcare Facilities
          1. By Value
        6. Others
          1. By Value
    11. Mexico
    12. Argentina
    13. Chile
    14. Colombia
    15. Rest of LATAM
  14. Competitive Landscape
    1. Infectious Disease Point-of-Care Diagnostics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
  15. Market Players Assessment
    1. Abbott (US)
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Hoffmann-La Roche Ltd. (Switzerland)
    3. Danaher Corporation (US)
    4. bioMérieux SA (France)
    5. Becton, Dickinson and Company (US)
    6. Thermo Fisher Scientific Inc. (US)
    7. Siemens Healthineers AG (Germany)
    8. QuidelOrtho Corporation (US)
    9. QIAGEN N.V. (Netherlands)
    10. Hologic, Inc. (US)
    11. DiaSorin S.p.A. (Italy)
    12. Grifols S.A. (Spain)
    13. Bio-Rad Laboratories, Inc. (US)
    14. Sysmex Corporation (Japan)
    15. OraSure Technologies, Inc. (US)
    16. Revvity, Inc. (US)
  16. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  17. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  18. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.